The discovery of the Role of Flolan

1. Epoprostenol is an intravenous medication approved for the treatment of pulmonary arterial hypertension (PAH) in World Health Organization (WHO) Group 1 patients.
2. It is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels.
3. Epoprostenol was the first therapy to be approved for the treatment of PAH.
4. Epoprostenol is also known by the trade name Flolan.
5. It has been an essential treatment for PAH for the past two decades and remains a critical treatment.

Some historical landmarks

• 976: Prostacyclin (PGI2), a natural vasodilator, is discovered by Vane and Moncada.
• 1980s: PGI2 is shown to be effective in treating pulmonary hypertension in animal models.
• 1988: The first clinical trial of intravenous epoprostenol for pulmonary hypertension is conducted, showing promising results.
• 1995: Epoprostenol is approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
• 2000: Epoprostenol is approved by the FDA for the treatment of pulmonary hypertension associated with scleroderma.
• 2004: The first inhaled formulation of epoprostenol is approved by the FDA.
• 2010: A new formulation of epoprostenol is approved by the FDA for the treatment of PAH associated with scleroderma, lupus erythematosus, and idiopathic PAH.

Action plan

1. xxxxx
2. fffff
3. gggggg
4. etc

Project’s Who is who

1. Dr. ggggggg
2. fffff gg gg , MD
3. tttttt fddfdfdf df

References and bibliography

1. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
2. LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN)
3. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.